In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Efficacy of stereotactic radiosurgery in recurrent oligodendroglioma

    Final Number:
    1285

    Authors:
    Seung-Yeob Yang MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: Stereotactic radiosurgery (SRS) is one salvage treatment option in previously irradiated patients with recurrent oligodendroglioma. We assessed the efficacy of SRS performed as a salvage treatment in 40 patients with recurrent low- and high-grade oligodendrogliomas.

    Methods: Forty patients with recurrent oligodendrogliomas underwent SRS at our radiosurgery. The mean patient age was 44.9 years (range, 11.0-72.0). Of these 40 patients, 34 received a full course of radiotherapy before SRS with a median dose of 56.4Gy in conventional fractionation and 13 received at least one chemotherapeutic regimen including procarbazine, cyclophosphamide, and vincristine. The mean time between primary diagnosis and SRS was 60.9 months (range, 4.1-146.0). The mean target volume was 5.10 cm3 (range, 0.1-25.6) and the mean margin dose was 16.2Gy (range, 10.0-23.0).

    Results: At a mean of 55.5 months of follow-up (range, 5.0-152.4) after GKRS, 20 patients were dead and 20 were living. Median overall survival after SRS was 106.7 months for patients with oligodendroglioma and 35.5 months for patients with anaplastic oligodendroglioma. Age at SRS, tumor recurrence after SRS, presence of neurological symptom, and tumor grade were significant in influencing overall survival after SRS. Median progression-free survival after GKRS was 31.3 months for oligodendroglioma and 15.7 months for anaplastic oligodendroglioma. Factors associated with an improved progression-free survival were presence of neurological symptom and tumor grade.

    Conclusions: SRS offers considerable treatment option as a salvage therapy for patients with smaller lesions of recurrent oligodendrogliomas.

    Patient Care: SRS offers considerable treatment option as a salvage therapy for patients with smaller lesions of recurrent oligodendrogliomas.

    Learning Objectives: SRS can be applied safely for recurrent malignant gliomas of small target volume, while minimizing the risk for radiation-induced complications.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy